

Experience of Galavit use for treatment of bronchi and pulmonary pathologies

S. Kakukin, M. Kushkova, A Apikova, M. Abidov
Medical center of Professor M. Abidov „Medicor”
Centre of Modern Medicine, Russia

Diversity of pharmaceuticals and treatment methods used in pulmonology is influenced by the etiological factor of a pathology and by the state of immune system. These factors determine the efficiency of therapy in this area. Any contact of antigens with tissues of a respiratory system is accompanied by universal response schemes on the part of a respiratory epithelium both of local and general significance. This excitation is oriented on the decay and elimination of antigens and antigen carriers from the body and has general launchinc, mechanisms irrespective of the substrates with antigen information.

Taking into account the unique mechanisms of Galavit, we used it for the treatment of such diseases as relapsing obstructive bronchitis and bronchial asthma.

As a basis, it has been presupposed that bronchi reactivity shifts in obstructive pathologies are operated by the mechanisms responsible for hyperactive alveolar macrophages and bronchi epithelium macrophages.

Various reasons and etiological factors that lead to obstructive bronchi pathologies are explained by the contacts of respiratory system with a great number of antigens found in living and non-living nature as well as by mechanical, chemical, and other inritators. On the backroud of exquisite architectonics, great contacting surface, diverse mechanisms of physiological regulation for the implementation of the main vital ventilation function, bronchial tree remains on of the most vulnerable body organs.

All the data of pathological physiology an pathological morphology of obstructive bronchi syndromes and bronchial asthma might have been regarded as those coinciding with a notion of „vicious circle”^{1*} as well as this might have seemed true with various immnuologic impairments of cell an d humoral chains explaining spastic and hypersecretorial malfunctions. However, no effective drugs have been developed till now capable of showing clinical effects that would have improved the symptomes of these pathologies. It confirms the opinion that these pharmaceuticals used for the treatment do not affect the key aspect of a „vicious circle”.

During the period from September 1997 till May 1998, patients with bronchi pathologies accompanied by expiratory obstructive syndrome have been treated in outpatient Service.

Affecting by Galavit the behaviour of hyperactive alveolar macrophages and bronchi epithelium macrophages, the normalization of cell chain and elimination of bronchi obstructive component were achieved.

Galavit's ability was established in the process of treatment to affect humoral chain of immunity. Positive moment was displayed by increased number of T-helper, Actually in all cases the relationship of T-helpers and T-suppressers was normalized. After the use of Galavit for not less than fifteen days, titer of reagig IgE antibodies has been decreased (during the period of twenty to thirty days) as well as the concetration of immune circulating complex (ICC).

Taking into account the above, Galavit was used in the treatment of bronchial asthma and relapsing obstructive syndromes of bronchistis in adults an children.

During Galavit treatment of bronchi and pulmonary pathologies, the positive effect was observed in the first hours after the first injection. The patients felt better, the depth of their breath was increased, edema reduced. Obstructive patients noted decreased rates of "attacks" from the first days of treatment. As a rule, the patients used inhalators much rarer.

A selected group of patients with bronchia asthma, besides intramuscular injections, received Galavit injections though ultrasound sprayer for local inhibiting of hyperactivated alveolar macrophages and not to admit leukocytes from vascular beds to alveoli. This was the most

effective combination of treatment for patients with pulmonary obstructions.

Some clinical cases of Galavit use for the treatment of respiratory pathologies have been cited in the Table.

Table 1

Diagnosis	Earlier prescriptions	Age of patient	Route of Galavit intake	Observed Effect after Galavit intake	Catarrhal history
Infectious-allergical bronchial asthma	Berotek for 7 years, to -20 times daily	63	Intramuscular injections	By the 6 th day Berotek was used 1-2 times a day	Clear positive effect
Infectious-allergical bronchial asthma	Asthmopent for 15 years every hour	30	Intramuscular injections	20 injections made	No attacks for 24 weeks
Obstruction of chronic bronchities	Eufellini for 3 years	55	Intramuscular injections, 10 inhalations 5 times a day	Complete recovery by the 15 th day	Healthy for 16 weeks
Atypical bronchial asthma	Hormones for 10 years, 240 mg, Asthmopent 20 times a day	44	Intramuscular injections, 25-15 inhalations	Hormones removed, Asthmopent 3-5 times a day	No severe attacks for 12 weeks
Obstructive bronchitis Acute insufficient breath of 2-3 degree		3	Intramuscular injections, 4 times	Complete recovery by me 5 th day	No relapses
Allergic Rhinitis, chronic maxillary sinusitis	Galasolin for 5 years 5-6 times a day	30	Intramuscular injections, 10 times, liniment	Recovery	Healthy for 12 weeks